Digestive Diseases Institute, Virginia Mason Medical Center, Seattle, WA, USA.
Division of Gastroenterology and Hepatology, Virginia Mason Medical Center, 1100 Ninth Avenue, Seattle, WA, 98101, USA.
Surg Endosc. 2020 May;34(5):1904-1913. doi: 10.1007/s00464-020-07409-7. Epub 2020 Feb 11.
In patients with acute cholecystitis who are deemed high risk for cholecystectomy, percutaneous cholecystostomy (PC) was historically performed for gallbladder drainage (GBD). There are several limitations associated with PC. Endoscopic GBD [Endoscopic transpapillary GBD (ET-GBD) and EUS-guided GBD (EUS-GBD)] is an alternative to PC. We performed a systematic review and meta-analysis to compare the effectiveness and safety of EUS-GBD versus ET-GBD.
We performed a systematic search of multiple databases through May 2019 to identify studies that compared outcomes of EUS-GBD versus ET-GBD in the management of acute cholecystitis in high-risk surgical patients. Pooled odds ratios (OR) of technical success, clinical success and adverse events between EUS-GBD and ET-GBD groups were calculated.
Five studies with a total of 857 patients (EUS-GBD vs ET-GBD: 259 vs 598 patients) were included in the analysis. EUS-GBD was associated with higher technical [pooled OR 5.22 (95% CI 2.03-13.44; p = 0.0006; I = 20%)] and clinical success [pooled OR 4.16 (95% CI 2.00-8.66; p = 0.0001; I = 19%)] compared to ET-GBD. There was no statistically significant difference in the rate of overall adverse events [pooled OR 1.30 (95% CI 0.77-2.22; p = 0.33, I = 0%)]. EUS-GBD was associated with lower rate of recurrent cholecystitis [pooled OR 0.33 (95% CI 0.14-0.79; p = 0.01; I = 0%)]. There was low heterogeneity in the analyses.
EUS-GBD has higher rate of technical and clinical success compared to ET-GBD. While the rates of overall adverse events are statistically similar, EUS-GBD has lower rate of recurrent cholecystitis. Hence, EUS-GBD is preferable to ET-GBD for endoscopic management of acute cholecystitis in select high-risk surgical patients.
在被认为胆囊切除术风险较高的急性胆囊炎患者中,经皮胆囊造口术(PC)历史上用于胆囊引流(GBD)。PC 存在多种局限性。内镜下 GBD(内镜经乳头 GBD [ET-GBD] 和 EUS 引导下 GBD [EUS-GBD])是 PC 的替代方法。我们进行了一项系统评价和荟萃分析,以比较 EUS-GBD 与 ET-GBD 在高危手术患者急性胆囊炎治疗中的有效性和安全性。
我们通过 2019 年 5 月对多个数据库进行了系统搜索,以确定比较 EUS-GBD 与 ET-GBD 在管理高危手术患者急性胆囊炎方面的结果的研究。计算 EUS-GBD 与 ET-GBD 组之间技术成功率、临床成功率和不良事件的汇总优势比(OR)。
纳入了五项研究,共 857 例患者(EUS-GBD 与 ET-GBD:259 例与 598 例)。EUS-GBD 与更高的技术[汇总 OR 5.22(95%CI 2.03-13.44;p=0.0006;I=20%)]和临床成功率[汇总 OR 4.16(95%CI 2.00-8.66;p=0.0001;I=19%)]相关。EUS-GBD 与 ET-GBD 相比,总体不良事件发生率无统计学差异[汇总 OR 1.30(95%CI 0.77-2.22;p=0.33,I=0%)]。EUS-GBD 与较低的复发性胆囊炎发生率相关[汇总 OR 0.33(95%CI 0.14-0.79;p=0.01;I=0%)]。分析中存在低异质性。
与 ET-GBD 相比,EUS-GBD 的技术和临床成功率更高。虽然总体不良事件发生率在统计学上相似,但 EUS-GBD 的复发性胆囊炎发生率较低。因此,在选择高危手术患者时,EUS-GBD 是急性胆囊炎内镜治疗的首选方法。